Antiproliferation effect of beta-TrCP ubiquitin ligase mediated BCR-ABL protein degradation in leukemia K562 cells

Chinese Journal of Clinical Oncology

Volumn 37, Issue 2, 2010, Pages 66-70

  Tian, Wenjun ^a   Lou, Hongwei ^a   Yuan, Ying ^a   Huang, Shifeng ^a   Liu, Dingbin ^a   Tao, Kun ^a   Feng, Wenli ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

BCR ABL fusion protein; Cell proliferation; K562 cells; Ubiquitin ligase TrCP

Indexed keywords

BCR ABL PROTEIN; GREEN FLUORESCENT PROTEIN; METHYLCELLULOSE; PROTEASOME; RECOMBINANT PROTEIN; UBIQUITIN; UBIQUITIN LIGASE BETA TRCP; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ADENOVIRUS; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COUNT; CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HEK293; CELL STRAIN K 562; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FLOW CYTOMETRY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; INFECTION RATE; NONHUMAN; ONCOGENE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS RECOMBINANT; WESTERN BLOTTING; WILD TYPE;

EID: 77149125624     PISSN: 16727118     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.2010.02.002     Document Type: Article

References (11)

1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment[J]. N Engl J Med, 2003, 349(15): 1451-1464.
2. Strous GJ, Govers R. The ubiquitin-proteasome system and endocytosis[J]. J Cell Sci, 1999, 112(Pt 10): 1417-1423.
3. Marx J. Ubiquitin lives up to its name|J]. Science, 2002, 297(5588): 1792-1794.
4. Guo XY, Cuillerot JM, Wang T, et al. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells[J]. Oncogene, 1998, 17(7): 825-833.
5. Kinoshita T, Sawai N, Hidaka E, et al. Interleukin-6 directly modulates stem cell factor-dependent development of human mast cells derived from CD34(+) cord blood cells[J]. Blood, 1999, 94(2):496-508.
6. Chinese source
7. Rubin BP, Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors[J]. Lab Invest, 2006, 86(10): 981-986.
8. Thomas M, Greil J, Heidenreich O. Targeting leukemic fusion proteins with small interfering RNAs: recent advances and therapeutic potentials[J]. Acta Pharmacol Sin, 2006, 27(3): 273-281.
9. Clark RE. Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems[J]. Leukemia, 2000, 14(3): 347-355.
10. Nakayama KI, Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases[J]. Semin Cell Dev Biol, 2005, 16(3): 323-333.
11. Sakamoto KM, Kim KB, Kumagai A, et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation[J]. Proc Nad Acad Sci U S A, 2001, 98(15): 8554-8559.